Feasibility of Neoadjuvant Immune Checkpoint Blockade for Resectable Diffuse Pleural Mesothelioma Along Potential of ctDNA Analyses to Detect Residual Disease By Ogkologos - September 22, 2025 389 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase II study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR FDA Approves Blinatumomab as Consolidation for CD19-positive Philadelphia Chromosome-negative B-Cell Precursor... August 6, 2024 5-Yr-Old Has Cutest Celebration With Big Brother After Being Declared Cancer-Free. May 21, 2019 Getting cancer services back on track during the COVID-19 pandemic June 22, 2020 Breast Cancer Patient Turns Hospital Robes Into Fashion with ‘Radiation Runway’ February 1, 2022 Load more HOT NEWS Pediatric MATCH Study Finds More Targetable Genetic Changes than Expected Is a Genomic Test Better at Finding Aggressive Prostate Cancer? Opinion: ‘Let’s not be short-sighted – the UK’s medical research charities... Reflections from our chief scientist: The rise of the whole organism
